ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids.
3D model
ADAM17
chemotherapy resistance
combined therapy
drug testing
multicontent readout
ovarian cancer
primary cells
primary spheroids
spheroids
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
08
03
2021
revised:
15
04
2021
accepted:
22
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Chemotherapy resistance is a major challenge in ovarian cancer (OvCa). Thus, novel treatment combinations are highly warranted. However, many promising drug candidates tested in two-dimensional (2D) cell culture have not proved successful in the clinic. For this reason, we analyzed our drug combination not only in monolayers but also in three-dimensional (3D) tumor spheroids. One potential therapeutic target for OvCa is A disintegrin and metalloprotease 17 (ADAM17). ADAM17 can be activated by chemotherapeutics, which leads to enhanced tumor growth due to concomitant substrate cleavage. Therefore, blocking ADAM17 during chemotherapy may overcome resistance. Here, we tested the effect of the ADAM17 inhibitor GW280264X in combination with cisplatin on ovarian cancer cells in 2D and 3D. In 2D, the effect on five cell lines was analyzed with two readouts. Three of these cell lines formed dense aggregates or spheroids (HEY, SKOV-3, and OVCAR-8) in 3D and the treatment effect was analyzed with a multicontent readout (cytotoxicity, viability, and caspase3/7 activation). We tested the combined therapy on tumor spheroids derived from primary patient cells. In 2D, we found a significant reduction in the half minimal (50%) inhibitory concentration (IC
Identifiants
pubmed: 33922533
pii: cancers13092039
doi: 10.3390/cancers13092039
pmc: PMC8122950
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncol Rep. 2013 Apr;29(4):1371-8
pubmed: 23338561
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
Mol Cancer Res. 2007 Dec;5(12):1246-53
pubmed: 18171982
Stem Cell Rev Rep. 2017 Jun;13(3):347-363
pubmed: 28233276
Biomaterials. 2010 Nov;31(32):8494-506
pubmed: 20709389
EMBO J. 2003 Jun 2;22(11):2704-16
pubmed: 12773386
Oncotarget. 2018 Apr 24;9(31):21893-21903
pubmed: 29774110
Oncotarget. 2018 Mar 23;9(22):16043-16058
pubmed: 29662625
Nat Commun. 2016 May 10;7:11523
pubmed: 27161080
Front Oncol. 2017 Dec 11;7:293
pubmed: 29322028
Clin Cancer Res. 2007 Apr 15;13(8):2335-43
pubmed: 17438092
Nature. 1999 Dec 23-30;402(6764):884-8
pubmed: 10622253
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
J Biol Chem. 2017 Apr 14;292(15):6339-6351
pubmed: 28232483
Sci Rep. 2020 Jul 28;10(1):12581
pubmed: 32724113
Oncotarget. 2016 Dec 6;7(49):81645-81660
pubmed: 27835572
Cancers (Basel). 2020 Sep 10;12(9):
pubmed: 32927828
Cancer Res. 1985 Oct;45(10):4970-9
pubmed: 3861241
Lancet Oncol. 2016 Nov;17(11):1579-1589
pubmed: 27617661
J Mol Med (Berl). 2006 Aug;84(8):671-81
pubmed: 16607561
Oncogene. 2018 Sep;37(37):5127-5135
pubmed: 29789717
Mediators Inflamm. 2017;2017:9673537
pubmed: 29230082
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
pubmed: 16829981
Blood. 2007 Sep 15;110(6):1748-55
pubmed: 17567983
Blood. 2003 Aug 15;102(4):1186-95
pubmed: 12714508
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Cancer Res. 2006 Sep 15;66(18):9045-53
pubmed: 16982746
Int J Cancer. 1994 Aug 1;58(3):393-9
pubmed: 7519585
Oncotarget. 2017 Jan 17;8(3):4008-4042
pubmed: 28008141
Sci Rep. 2020 Feb 3;10(1):1653
pubmed: 32015396
Hum Pathol. 2005 Mar;36(3):242-9
pubmed: 15791568
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Biology (Basel). 2020 Dec 04;9(12):
pubmed: 33291824
Sci Rep. 2016 Dec 16;6:35598
pubmed: 27982031
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
pubmed: 18058370
Nat Biotechnol. 2014 Jan;32(1):40-51
pubmed: 24406927
Int J Cancer. 1990 Mar 15;45(3):416-22
pubmed: 2307530
Med Oncol. 2012 Dec;29(4):2684-90
pubmed: 22139867
PLoS One. 2013;8(3):e58226
pubmed: 23554878
J Cell Biol. 2004 Mar 1;164(5):769-79
pubmed: 14993236
Int J Cancer. 2013 Oct 1;133(7):1557-66
pubmed: 23526433
Oncogene. 2016 Jan 28;35(4):438-47
pubmed: 25915843
Exp Biol Med (Maywood). 2016 May;241(9):939-54
pubmed: 27072562
Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43
pubmed: 15688065
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Tumour Biol. 2016 Sep 22;:
pubmed: 27658778
Transl Oncol. 2009 Aug 18;2(3):164-73
pubmed: 19701501
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Cancer Cell Int. 2020 Oct 21;20:516
pubmed: 33100908
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Methods Mol Biol. 2011;731:161-80
pubmed: 21516407
Int J Mol Med. 2019 Feb;43(2):914-926
pubmed: 30569104
Arch Gynecol Obstet. 2016 Aug;294(2):369-76
pubmed: 26825732
Oncogene. 2007 May 3;26(20):2860-72
pubmed: 17072341
PLoS One. 2012;7(7):e40597
pubmed: 22792380
Cell Mol Life Sci. 2018 Feb;75(3):509-525
pubmed: 28956065
Crit Rev Biochem Mol Biol. 2010 Apr;45(2):146-69
pubmed: 20184396
Gynecol Oncol. 2010 Jan;116(1):61-5
pubmed: 19840886
Neuro Oncol. 2014 Mar;16(3):382-91
pubmed: 24327582
J Leukoc Biol. 2020 Jun;107(6):1081-1095
pubmed: 31833593
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Comb Chem High Throughput Screen. 2005 Mar;8(2):161-71
pubmed: 15777180
J Exp Med. 2018 Apr 2;215(4):1205-1225
pubmed: 29472497
Clin Cancer Res. 2010 Jul 1;16(13):3378-89
pubmed: 20570921